Keywords: Antipsychotic drugs, Warning label, USA. FDA, Newborns, Johnson & Johnson, Novartis, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Pfizer
US FDA calls for antipsychotic drug labels to reflect risk to newborns
Article | 23 February 2011
The US Food and Drug Administration yesterday told health care professionals that it has updated the Pregnancy section of drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
